The US FDA has approved semaglutide to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD). Clinical evidence The efficacy of semaglutide was evaluated in a clinical trial involving 3,533 adults with T2D and CKD.
In the trial, a once-weekly injection of semaglutide (1 mg) significantly reduced the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease by 24% compared to a placebo. Dosage and administration Available as an injectable prescription medicine (0.5 mg, 1 mg, or 2 mg) Administer along with diet and exercise Contraindications Patients with or have a family history of medullary thyroid carcinoma (MTC) Patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) Warnings and precautions Risk of thyroid tumors Pancreatitis Changes in vision Hypoglycemia…
